U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07099235) titled 'Chart Review of Patients Undergoing Ketamine Treatments for Depression' on July 20.
Brief Summary: The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.
Study Start Date: April 01, 2022
Study Type: OBSERVATIONAL
Condition:
Depression - Major Depressive Disorder
Intervention: ...